U.S. markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
19.25-0.31 (-1.58%)
At close: 4:00PM EST

19.25 0.00 (0.00%)
After hours: 4:20PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close19.56
Open19.45
Bid18.51 x 800
Ask19.25 x 900
Day's Range18.71 - 19.95
52 Week Range9.01 - 20.46
Volume1,249,808
Avg. Volume709,433
Market Cap903.154M
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-3.99
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Aerie Surpasses $1 Billion in Revenues; More Offline by Aerie Stores Coming
    WWD

    Aerie Surpasses $1 Billion in Revenues; More Offline by Aerie Stores Coming

    Meanwhile, the retailer expects current quarter revenues to grow, compared with the first quarters of 2019 and 2020.

  • Benzinga

    Looking Into Aerie Pharmaceuticals's Return On Capital Employed

    During Q4, Aerie Pharmaceuticals's (NASDAQ:AERI) reported sales totaled $24.68 million. Despite a 5.92% in earnings, the company posted a loss of $35.59 million. Aerie Pharmaceuticals collected $20.08 million in revenue during Q3, but reported earnings showed a $33.60 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Aerie Pharmaceuticals posted an ROCE of -1.49%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on AERI ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Aerie Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. In Aerie Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Insight Aerie Pharmaceuticals reported Q4 earnings per share at $-0.79/share, which did not meet analyst predictions of $-0.73/share. See more from BenzingaClick here for options trades from BenzingaReturn On Capital Employed Overview: SnapWhy Is It Moving? Looking Into Why Airbnb's Stock is Trading Lower Today© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
    Zacks

    Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark

    Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.